Availability of the Bβ(15-21) Epitope on Cross-Linked Human Fibrin and Its Plasmic Degradation Products

Summary

The binding of radiolabeled monoclonal antifibrin antibody 59D8 (specific for fibrin but not fibrinogen) to a series of degraded fibrin clots showed that the availability of the Bβ(15-21) epitope (against which 59D8 had been raised) was inversely proportional to the extent of clot lysis. Examination of digest supernatants revealed that the Bβ(15-21) epitope was released from clots as a high molecular weight degradation product in the presence of calcium ions but that the generation of low molecular weight peptides occurred in the absence of calcium ions. To address the question of epitope accessibility, we compared levels of fibrin clot binding among four radioactively labeled antibodies: antifibrin monoclonal antibody 59D8, two antifibrinogen monoclonal antibodies that cross-reacted with fibrin, and an affinity-purified polyclonal antifibrinogen antibody. We expected that the antifibrinogen antibodies would show enhanced binding to clots in comparison with the antifibrin antibody. However, the epitope accessibility experiments showed that all four antibody preparations bound fibrin clots at comparable levels. Taken together, these studies demonstrated that one fibrin-specific epitope, Bβ(15-21), remains available on clots as they undergo degradation by plasmin and, importantly, that the epitope is not solubilized at a rate faster than the rate at which the clot is itself solubilized. The availability of the Bβ(15-21) epitope during the course of plasminolysis assures the potential utility of antifibrin antibodies such as 59D8 for detecting thrombi and targeting plasminogen activators.

• References

• 1 Day ED, Planinsek JA, Pressman D. Localization in vivo of radioiodi-nated anti-rat-fibrin antibodies and radioiodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors. J Natl Cancer Inst 1959; 22: 413-426
• 2 Bale WF, Spar IL, Goodland RL. Experimental radiation therapy of tumors with ¹³¹I-carrying antibodies to fibrin. Cancer Res 1960; 20: 1488-1494
• 3 Edgington TS, Plow EF. Functional molecular anatomy of fibrinogen: antibodies as biological probes of structure. Contemp Top Mol Immunol 1973; 2: 237-271
• 4 Pacella Jr BL, Hui KY, Haber E, Matsueda GR. Induction of fibrin-specific antibodies by immunization with synthetic peptides that correspond to amino termini of thrombin cleavage sites. Mol Immunol 1983; 20: 521-527
• 5 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132
• 6 Liau CS, Haber E, Matsueda GR. Evaluation of monoclonal antifibrin antibodies by their binding to human blood clots. Thromb Haemostas 1987; 57: 49-54
• 7 Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 1985; 229: 765-767
• 8 Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sei USA 1987; 84: 6904-6908
• 9 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH₂-terminal region of fibrin. Mol Immunol 1984; 21: 89-94
• 10 Rosebrough SF, Kudryk B, Grossman ZD, McAfee JG, Subramanian G, Ritter-Hmcirik CA, Witanowski LS, Tillapaugh-Fay G. Radio-immunoimaging of venous thrombi using iodine-131 monoclonal antibody. Radiology 1985; 156: 515-517
• 11 Wasser MN, Pauwels EK, Nieuwenhuizen W. Thrombus detection using a Tc-99m labeled antifibrin monoclonal antibody (MoAb). Experiments in vitro and in animals. Thromb Res Suppl 1990; 10: 91-104
• 12 Holvoet P, Stassen JM, Hashimoto Y, Spriggs D, Devos P, Collen D. Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits. Thromb Haemostas 1989; 61: 307-313
• 13 Liau CS, Su CT. Imaging of experimental arterial thrombi with iodine-131-labeled fibrin-specific monoclonal antibody. J Formosan Med Assoc 1989; 88: 209-212
• 14 Kanke M, Matsueda GR, Strauss HW, Yasuda T, Liau CS, Khaw BA. Localization and visualization of pulmonary emboli with radiolabeled fibrin-specific monoclonal antibody. J Nucl Med 1991; 32: 1254-1260
• 15 Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. In: Hemostasis and Thrombosis. 2nd edition. Colman RW, Hirsch J, Marder VJ, Salzman EW. (eds) J B Lippincott; Philadelphia, PA: 1987. pp 358-379
• 16 Budzynski AZ. Fibrinogen and fibrin: biochemistry and pathophysiology. CRC Crit Rev Oncol/Haematol 1986; 6: 97-146
• 17 Matsueda GR, Bernatowicz MS. In: Fibrinogen 3 - Biochemistry, Biological Functions, Gene Regulation and Expression. Mosesson MW, Amrani DL, Siebenlist KR, DiOrio JP. (eds) Elsevier; Amsterdam,: 1988. pp 133-136
• 18 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloramide. Biochem Biophys Res Commun 1978; 80: 849-857
• 19 Lijnen HR, Marafino Jr BJ, Collen D. In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species. Thromb Haemostas 1984; 52: 308-310
• 20 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res 1977; 10: 803-812
• 21 Olexa SA, Budzynski AZ, Doolittle RF, Cottrell BA, Greene TC. Structure of fragment E species from human cross-linked fibrin. Biochemistry 1981; 20: 6139-6145
• 22 Francis CW, Marder VJ, Martin SE. Plasmic degradation of cross-linked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood 1980; 56: 456-464
• 23 Brommer EJ. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res 1984; 34: 109-115
• 24 Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51-56
• 25 Liau CS. Antifibrin monoclonal antibody: its production, characterization and application in thrombus imaging. J Formosan Med Assoc 1988; 87: 339-345
• 26 Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: Targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 1987; 84: 7659-7662
• 27 Branscomb EE, Runge MS, Savard CE, Adams KM, Matsueda GR, Haber E. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator. Thromb Haemostas 1990; 64: 260-266